Vis enkel innførsel

dc.contributor.authorLi, Kuanrong
dc.contributor.authorHüsing, Anika
dc.contributor.authorFortner, Renée Turzanski
dc.contributor.authorTjønneland, Anne
dc.contributor.authorHansen, Louise Seier
dc.contributor.authorDossus, Laure
dc.contributor.authorChang-Claude, Jenny
dc.contributor.authorBergmann, Manuela M.
dc.contributor.authorSteffen, Annika
dc.contributor.authorBamia, Christina
dc.contributor.authorTrichopoulos, Dimitrios
dc.contributor.authorTrichopoulou, Antonia
dc.contributor.authorPalli, Domenico
dc.contributor.authorMattiello, Amalia
dc.contributor.authorAgnoli, Claudia
dc.contributor.authorTumino, Rosaria
dc.contributor.authorOnland-Moret, N. Charlotte
dc.contributor.authorPeeters, Petra H.
dc.contributor.authorBueno-de-Mesquita, H. Bas
dc.contributor.authorGram, Inger Torhild
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorSánchez-Cantalejo, Emilio
dc.contributor.authorChirlaque, María-Dolores
dc.contributor.authorDuell, Eric J.
dc.contributor.authorArdanaz, Eva
dc.contributor.authorIdahl, Annika
dc.contributor.authorLundin, Eva
dc.contributor.authorKhaw, Kay-Tee
dc.contributor.authorTravis, Ruth C.
dc.contributor.authorMerritt, Melissa A.
dc.contributor.authorGunter, Marc J.
dc.contributor.authorRiboli, Elio
dc.contributor.authorFerrari, Pietro
dc.contributor.authorTerry, Kathryn L.
dc.contributor.authorCramer, Daniel William
dc.contributor.authorKaaks, Rudolf
dc.date.accessioned2022-06-10T10:34:36Z
dc.date.available2022-06-10T10:34:36Z
dc.date.issued2015-03-05
dc.description.abstractBackground: Ovarian cancer has a high case-fatality ratio, largely due to late diagnosis. Epidemiologic risk prediction models could help identify women at increased risk who may benefit from targeted prevention measures, such as screening or chemopreventive agents.<p> <p>Methods: We built an ovarian cancer risk prediction model with epidemiologic risk factors from 202 206 women in the European Prospective Investigation into Cancer and Nutrition study. <p>Results: Older age at menopause, longer duration of hormone replacement therapy, and higher body mass index were included as increasing ovarian cancer risk, whereas unilateral ovariectomy, longer duration of oral contraceptive use, and higher number of full-term pregnancies were decreasing risk. The discriminatory power (overall concordance index) of this model, as examined with five-fold cross-validation, was 0.64 (95% confidence interval (CI): 0.57, 0.70). The ratio of the expected to observed number of ovarian cancer cases occurring in the first 5 years of follow-up was 0.90 (293 out of 324, 95% CI: 0.81–1.01), in general there was no evidence for miscalibration. <p>Conclusion: Our ovarian cancer risk model containing only epidemiological data showed modest discriminatory power for a Western European population. Future studies should consider adding informative biomarkers to possibly improve the predictive ability of the model.en_US
dc.identifier.citationLi K, Hüsing A, Fortner RT, Tjønneland A, Hansen, Dossus L, Chang-Claude J, Bergmann MM, Steffen A, Bamia C, Trichopoulos D, Trichopoulou A, Palli D, Mattiello A, Agnoli C, Tumino R, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HB, Gram IT, Weiderpass E, Sánchez-Cantalejo E, Chirlaque M, Duell EJ, Ardanaz E, Idahl A, Lundin E, Khaw K, Travis RC, Merritt MA, Gunter MJ, Riboli E, Ferrari P, Terry KL, Cramer, Kaaks R. An epidemiologic risk prediction model for ovarian cancer in Europe: The EPIC study. British Journal of Cancer. 2015;112(7):1257-1265en_US
dc.identifier.cristinIDFRIDAID 1277847
dc.identifier.doi10.1038/bjc.2015.22
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.urihttps://hdl.handle.net/10037/25445
dc.language.isoengen_US
dc.publisherNatureen_US
dc.relation.journalBritish Journal of Cancer
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7-IDEAS-ERC /232997/EU/TRANSCRIPTOMICS IN CANCER EPIDEMIOLOGY /TICE/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2015 Cancer Research UKen_US
dc.titleAn epidemiologic risk prediction model for ovarian cancer in Europe: The EPIC studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel